BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
From Loner to Force to be reckoned with: Individual Accounts of Change - 2Sexual violence part of 'everyday life' in parts of Sudan, charity says
- 3The Beginning Of The End For Fossil Fuels Can Start In Colombia
- 4How a seabird native to Hawaii has adapted to life in Honolulu's concrete jungle
- 55 Worldwide Road Food varieties You Should Attempt
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- Famous Versatile Brands: Your Decision
- The most effective method to Keep up with Proficient Handshakes in a Computerized World
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China
- 21 Things You Ought to Never Tell Your Childless Companion
